PreviousNextExpandCollapseSearch

Web Page-Disease

Disease Phase Study No. Summary Status Total
Hide details for Advanced CancersAdvanced Cancers
  107
Hide details for Phase IPhase I
  70
2015-0158   A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors  Open  
2015-0054   Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies  Open  
2015-0033   Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects with Advanced/Relapsed Solid Tumors  Open  
2015-0028   An Open-Label, Dose-escalation/expansion Phase 1 Study of ASP4132 Given Orally to Subjects with Advanced Refractory Solid Tumors and Lymphoma  Open  
2014-1056   Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects with Adult Solid Tumors  Open  
2014-1054   A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer  Open  
2014-1045   A phase I, gene alteration-based, open label, multicenter study of oral Debio 1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the FGFR 1, 2 or 3 genes  Open  
2014-1022   An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2  Open  
2014-1006   A Phase I Study of IDH305 in Patients with Advanced Malignancies that Harbor IDH1R132 Mutations  Open  
2014-0999   A Phase I, multicenter, open-label dose escalation and expansion study of PCA062, administered intravenously in adult patients with pCAD-positive tumors  Open  
2014-0959   A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects with Advanced Cancer  Open  
2014-0891   A Phase 1 study of KBP-5209 in patients with advanced solid tumors  Open  
2014-0878   A Multicenter Phase 1 Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors  Open  
2014-0763   Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors  Open  
2014-0640   Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies  Open  
2014-0605   A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors  Open  
2014-0495   A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors  Open  
2014-0384   A Phase 1 Dose-Escalation Study of LY2940680 in Patients with Advanced Cancer  Open  
2014-0338   A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients with Advanced or Metastatic Cancer   Open  
2014-0328   Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function  Open  
2014-0193   A Phase 1b Trial of LY2606368 in Combination with
Cisplatin or Cetuximab in Advanced and/or Metastatic
Tumors
  Open  
2014-0137   An open-label Phase I dose-escalation study to evaluate
the safety, tolerability, maximum tolerated dose,
pharmacokinetics, and pharmacodynamics of the anti-
C4.4a antibody drug conjugate BAY 1129980 in
subjects with advanced solid tumors known to express
C4.4a
  Open  
2013-0969   A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND
PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT PATIENTS WITH
ADVANCED SOLID TUMORS
  Open  
2013-0866   A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects with Advanced Malignancies  Open  
2013-0833   A Phase I Trial of Regorafenib and Cetuximab in Patients with Advanced Malignancy  Open  
2013-0823   A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1  Open  
2013-0813   A Phase Ib Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 plus BYL719 in Adult Patients with Selected Advanced Solid Tumors   Open  
2013-0765   Phase I Study of Fourth Ventricle Infusions of Autologous ex vivo-expanded NK Cells in children with recurrent/refractory malignant posterior fossa tumors of the central nervous system.
NOAH’s (New Opportunity, Advancing Hope) Protocol
  Open  
PreviousNextExpandCollapseSearch